The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes.
Ignace Vergote
Consultant or Advisory Role - Eisai
Honoraria - Eisai
Michael Teneriello
No relevant relationships to disclose
Matthew A. Powell
Consultant or Advisory Role - Arno Therapeutics; Eisai; GlaxoSmithKline; Merck; Novartis; Roche/Genentech
Honoraria - Ethicon; Merck
David S. Miller
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Agustin A. Garcia
No relevant relationships to disclose
Olga N. Mikheeva
No relevant relationships to disclose
Tamas Pinter
No relevant relationships to disclose
Mariusz Bidzinski
No relevant relationships to disclose
Cristina Ligia Cebotaru
No relevant relationships to disclose
Jean Fan
Employment or Leadership Position - Eisai
Min Ren
Employment or Leadership Position - Eisai
Nicole Meneses
Employment or Leadership Position - Eisai
Yasuhiro Funahashi
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
Tadashi Kadowaki
Employment or Leadership Position - Eisai
Stock Ownership - Eisai
James P. O'Brien
Employment or Leadership Position - Eisai
Richard T. Penson
Other Remuneration - Protocol Dev. Co.